Patents Assigned to Incyte Holdings Corporation
  • Heterocyclylamines as PI3K inhibitors
    Patent number: 10092570
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: October 9, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Wenyu Zhu, Joseph Glenn, Thomas P. Maduskuie, Jr., Richard B. Sparks, Brent Douty, Chunhong He
  • Bicyclic heterocycles as FGFR inhibitors
    Patent number: 10040790
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: August 7, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Yaping Sun, Liang Lu, Wenqing Yao, Chunhong He, Fenglei Zhang
  • 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
    Patent number: 10034864
    Abstract: The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: July 31, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu
  • Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
    Patent number: 10016429
    Abstract: The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: July 10, 2018
    Assignees: INCYTE CORPORATION, INCYTE HOLDINGS CORPORATION
    Inventors: James D. Rodgers, Hui-Yin Li
  • Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
    Patent number: 9999619
    Abstract: The present invention provides piperidin-4-yl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: June 19, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Taisheng Huang, Chu-Biao Xue
  • Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors
    Patent number: 9988387
    Abstract: The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: June 5, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Jincong Zhuo, Chunhong He, Wenqing Yao
  • Pyrimidinones as PI3K inhibitors
    Patent number: 9975907
    Abstract: The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: May 22, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
  • Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
    Patent number: 9974790
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: May 22, 2018
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: James D. Rodgers, Stacey Shepard
  • Amido compounds and their use as pharmaceuticals
    Patent number: 9957229
    Abstract: The present invention relates to inhibitors of 11-? hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-? hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: May 1, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Wenqing Yao, Jincong Zhuo, Meizhong Xu, Colin Zhang, Brian W. Metcalf, Chunhong He, Ding-Quan Qian
  • Imidazotriazines and imidazopyrimidines as kinase inhibitors
    Patent number: 9944645
    Abstract: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: April 17, 2018
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao
  • Bicyclic azaheterocyclobenzylamines as PI3K inhibitors
    Patent number: 9944646
    Abstract: The present invention provides bicyclic azaheterocyclobenzylamines of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: April 17, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, Jr.
  • Tricyclic heterocycles as BET protein inhibitors
    Patent number: 9938294
    Abstract: The present invention relates to tricyclic heterocycles of Formula (I): which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: April 10, 2018
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, Jr., James D. Rodgers
  • Use of pyrazolopyrimidine derivatives for the treatment of PI3K-delta related disorders
    Patent number: 9932341
    Abstract: The present application provides methods of treating PI3K? related disorders using compounds of Formula I: or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: April 3, 2018
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Andrew P. Combs, Eddy W. Yue, Song Mei, Brent Douty
  • Processes for preparing pyrazolyl-substituted pyrrolo[2,3-d]pyrimidines
    Patent number: 9908888
    Abstract: The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: March 6, 2018
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Jiacheng Zhou, Pingli Liu, Qiyan Lin, Brian W. Metcalf, David Meloni, Yongchun Pan, Michael Xia, Mei Li, Tai-Yuen Yue, James D. Rodgers, Haisheng Wang
  • Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b] pyrimidin-5-yl-amines as Janus kinase inhibitors
    Patent number: 9879010
    Abstract: The present invention provides pyrrolo[2,3-b]pyridine-4-yl amines pyrrolo[2,3-b]pyrimidin-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: January 30, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: James D. Rodgers, Haisheng Wang, Andrew P. Combs, Richard B. Sparks
  • Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1
    Patent number: 9873698
    Abstract: The present invention relates to certain spirocyclic compounds that are inhibitors of 11-? hydroxyl steroid dehydrogenase type 1 (11?HSD1), compositions containing the same, and methods of using the same for the treatment of diabetes, obesity and other diseases.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: January 23, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Wenqing Yao, Jincong Zhuo, Colin Zhang
  • Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
    Patent number: 9873688
    Abstract: The present application is directed to processes and intermediates for making 4-({2-[(aminosulfonyl)amino]ethyl}amino)-N-(3-bromo-4-fluorophenyl)-N?-hydroxy-1,2,5-oxadiazole-3-carboximidamide, which is an inhibitor of indoleamine 2,3-dioxygenase, useful in the treatment of cancer and other disorders.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: January 23, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Ming Tao, William Frietze, David J. Meloni, Lingkai Weng, Jiacheng Zhou, Yongchun Pan
  • Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
    Patent number: 9849120
    Abstract: The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use. The compounds inhibit the activity of the Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: December 26, 2017
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Chu-Biao Xue, Yun-Long Li, Hao Feng, Ke Zhang
  • Tricyclic heterocycles as BET protein inhibitors
    Patent number: 9850257
    Abstract: The present invention relates to tricyclic heterocycles of Formula (I), which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: December 26, 2017
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Andrew P. Combs, Eddy W. Yue, Thomas P. Maduskuie
  • N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
    Patent number: 9815839
    Abstract: The present invention provides N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines derivatives that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: November 14, 2017
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Andrew P. Combs, Eddy W. Yue, Thomas P. Maduskuie, Jr., Richard B. Sparks